P-001

P-001 is an investigational drug candidate currently in development by Pangea Pharmaceuticals for the treatment of allergic conditions. Pangea Pharmaceuticals is a specialty pharmaceutical company that primarily focuses on the development and commercialization of reformulated or generic versions of existing drug products. As P-001 is a pipeline code, specific details regarding its active pharmaceutical ingredient, molecular target, and formulation have not been publicly disclosed. Given the company's business model, P-001 is likely a small molecule therapeutic intended to provide a generic or improved alternative to established allergy medications.